Pierre G Coulie

This inventor holds 53 USPTO granted patents and 2 published patent applications, plus 1 CIPO patent and 4 EPO patents, primarily in Tumor Immunology (CPC class C07K). Top assignees: Ludwig Institute for Cancer Research Limited, Universitè Catholique De Louvain, Argenx Bvba. Active years: 1992-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Pierre G Coulie. Retrieved from https://idiyas.com/inventor/pierre-g-coulie

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 53 (Patent Applications = 2)

% Patents Active = 96.2

CIPO Patents = 1

EPO Patents = 4 (Patent Applications = 5)

Average Co-Inventor Count = 4.5

ph-index = 11

Forward Citations = 341(Granted Patents)

Forward Citations (Not Self Cited) = 330(Dec 10, 2025)

Inventors with similar research interests:

Location History:

Brussels, BE (1996 - 2012)
Kraainem, BE (1992 - 2022)

Company Filing History:

46 out of 530

Ludwig Institute for Cancer Research Limited

patents

6 out of 100

Universitè Catholique De Louvain

Oxford University Innovation Ltd

patents

5. 1 out of 101

Institut Gustave Roussy

patents

6. 1 out of 3

Ludwig Institute of Cancer Research

patents

7. 1 out of 1,853

National Institute of Health and Medical Research

patents

8. 1 out of 1

Université Catholique De Louvian

patent

9. 1 out of 834,513

Other

patents

where one patent can have more than one assignee

Years Active: 1992-2022

Loading Chart...

Areas of Expertise:

GARP Protein

TGF-Beta Antibodies

MAGE Antigens

Tumor Rejection

Nucleic Acids

HLA Molecules

Cancer Screening

Immunogenic Compositions

Peptide Complexes

Leukemia Genes

Monoclonal Antibodies

Cellular Abnormalities

53 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11230603 - Anti-GARP protein (2022-01-25),

2. 10875914 - Nucleic acids encoding GARP-TGF-beta 1 antibodies (2020-12-29),

3. 10822424 - Method of screening for anti-GARP antibodies (2020-11-03),

4. 10793627 - GARP-TGF-β 1 IGG antibodies (2020-10-06),

5. 10604579 - Antibody against a complex between human GARP and latent TGF-β (2020-03-31),

6. 10479829 - GARP-TGF-beta 1 antibodies (2019-11-19),

7. 10000572 - Method for inhibiting the immune suppressive function of human T regulatory cells by administering an anti-GARP monoclonal antibody (2018-06-19),

8. 8492342 - Preprocalcitonin antigen T epitopes (2013-07-23),

9. 8143011 - MAGE-C2 antigenic peptides and uses thereof (2012-03-27),

10. 7547517 - MAGE-C2 antigenic peptides and uses thereof (2009-06-16),

11. 6770456 - Endogenous retrovirus tumor associated nucleic acids and antigens (2004-08-03),

12. 6682731 - Isolated peptides derived from mage tumor rejection antigen precursors which complex with HLA-A2 molecules (2004-01-27),

13. 6680056 - METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HLA-CW 1601/MAGE-1 DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS (2004-01-20),

14. 6669946 - METHOD FOR IDENTIFYING INDIVIDUALS SUFFERING FROM A CELLULAR ABNORMALITY SOME OF WHOSE ABNORMAL CELLS PRESENT COMPLEXES OF HUMAN LEUKOCYTE ANTIGEN TYROSINASE DERIVED PEPTIDES, AND METHODS FOR TREATING SAID INDIVIDUALS (2003-12-30),

15. 6638512 - Method for treating subjects by using BAGE tumor rejection antigen precursors or tumor rejection antigens (2003-10-28),

Title: Pierre G. Coulie: A Trailblazer in Biotechnology Innovation

Introduction: Pierre G. Coulie is a renowned inventor based in Brussels, Belgium, whose dedication to innovation has significantly impacted the field of biotechnology. With an impressive portfolio of 53 patents, Coulie's groundbreaking inventions have revolutionized healthcare and earned him a distinguished reputation as a pioneering inventor.

Latest Patents: Among his latest patents is the "Anti-GARP protein," which focuses on a protein binding to GARP in the presence of TGF-β and its varied uses. Another significant patent is "Nucleic acids encoding GARP-TGF-beta 1 antibodies," which highlights antibodies and antigen binding fragments that inhibit the release of active TGF-β from regulatory T cells. These inventions showcase Coulie's commitment to developing solutions that enhance the effectiveness and stability of biotechnological advancements.

Career Highlights: Coulie has made substantial contributions to the biotechnology sector through his work with prominent companies such as the Ludwig Institute for Cancer Research Limited and Argenx Bvba. His innovative approach to research and development has led to the creation of groundbreaking technologies that have the potential to transform the healthcare industry.

Collaborations: Throughout his career, Coulie has collaborated with esteemed professionals in the field, including Thierry R. Boon-Falleur and Pierre Van Der Bruggen. These partnerships have been instrumental in driving forward his research efforts and have resulted in the successful development of pioneering inventions.

Conclusion: Pierre G. Coulie's unwavering passion for innovation and his dedication to advancing biotechnology have solidified his position as a trailblazer in the industry. Through his extensive patent portfolio and collaboration with industry experts, Coulie continues to shape the future of healthcare with his transformative inventions.

Profile summary based on public USPTO records.